Rockwell Medical Plunges to $4.76M Loss Amidst Sales Slump

TL;DR

**RMTI is bleeding cash and sales are tanking; steer clear until they prove they can turn this ship around.**

AI Summary

Rockwell Medical, Inc. (RMTI) reported a significant decline in financial performance for the nine months ended September 30, 2025, with net sales plummeting to $50.912 million from $76.824 million in the prior year, a 33.7% decrease. This led to a net loss of $4.760 million, a stark contrast to the net income of $0.276 million reported for the same period in 2024. The company's gross profit also fell sharply to $7.817 million from $13.853 million, a 43.6% reduction. Operating loss for the nine months was $4.293 million, compared to an operating income of $1.127 million in 2024. Cash and cash equivalents decreased to $13.610 million as of September 30, 2025, from $15.662 million at December 31, 2024, with net cash used in operating activities totaling $2.950 million. The company closed its manufacturing facility in Greer, South Carolina, in Q3 2025 to streamline operations, incurring $0.8 million in closure-related costs. Despite these losses, management believes it has sufficient funds for the next twelve months, supported by $23.7 million in cash, cash equivalents, and available-for-sale investments, and $13.1 million available under its at-the-market (ATM) facility.

Why It Matters

This filing reveals a concerning financial downturn for Rockwell Medical, with significant revenue and profit declines that could impact investor confidence and future growth prospects. The company's shift from net income to a substantial net loss, coupled with negative operating cash flow, signals potential challenges in its core hemodialysis product market. For employees, the closure of the South Carolina manufacturing facility indicates ongoing operational restructuring, which could lead to further workforce adjustments. Customers might see potential impacts on product availability or pricing if the company struggles to regain profitability. In a competitive healthcare market, RMTI's struggles could open opportunities for rivals, while its reliance on an ATM facility for future capital raises highlights liquidity concerns.

Risk Assessment

Risk Level: high — The company reported a net loss of $4.760 million for the nine months ended September 30, 2025, a significant deterioration from a net income of $0.276 million in the prior year. Net cash used in operating activities was $2.950 million, indicating ongoing cash burn. The substantial 33.7% drop in net sales from $76.824 million to $50.912 million highlights severe operational challenges and market pressure.

Analyst Insight

Investors should exercise extreme caution and consider divesting RMTI shares given the substantial net loss, declining sales, and negative operating cash flow. Monitor future filings closely for signs of successful customer acquisition, effective cost containment, and a return to profitability before considering any new investment.

Financial Highlights

revenue

$50.912M

total Assets

$57.486M

total Debt

$20.466M

net Income

$(4.760)M

eps

$(0.14)

gross Margin

15.35%

cash Position

$13.610M

revenue Growth

-33.7%

Key Numbers

• $50.912M — Net Sales (Decreased from $76.824M for the nine months ended September 30, 2024)
• $(4.760)M — Net Loss (Compared to net income of $0.276M for the nine months ended September 30, 2024)
• $(2.950)M — Net Cash Used In Operating Activities (For the nine months ended September 30, 2025, compared to $3.337M provided in 2024)
• $13.610M — Cash and Cash Equivalents (As of September 30, 2025, down from $15.662M at December 31, 2024)
• $23.7M — Cash, Cash Equivalents and Investments Available-for-Sale (Total liquidity as of September 30, 2025)
• $13.1M — Available under ATM facility (Potential source of additional capital)
• $0.8M — Severance and closure-related costs (Incurred for the nine months ended September 30, 2025, due to South Carolina facility closure)
• 39,405,302 — Shares of Common Stock Outstanding (As of November 7, 2025)
• $(0.14) — Basic Net Loss per Share (For the nine months ended September 30, 2025, compared to $0.01 income per share in 2024)
• $27.9M — Net Working Capital (As of September 30, 2025)

Key Players & Entities

• ROCKWELL MEDICAL, INC. (company) — registrant
• Innovatus Life Sciences Lending Fund I, LP (company) — lender under Loan Agreement
• Greer, South Carolina (location) — site of closed manufacturing facility
• U.S. Securities and Exchange Commission (regulator) — filing recipient
• Nasdaq Capital Market (market) — exchange where RMTI Common Stock is registered
• Rockwell Transportation, Inc. (company) — wholly-owned subsidiary
• Rockwell Medical India Private Limited (company) — wholly-owned subsidiary
• Delaware (location) — state of re-domiciliation in 2019
• Michigan (location) — state of incorporation in 1996 and headquarters location
• P.L. 119-21 (other) — U.S. federal statute enacted July 4, 2025

FAQ

Risk Factors

• Significant Decline in Net Sales [high — operational]: Net sales decreased by 33.7% to $50.912 million for the nine months ended September 30, 2025, from $76.824 million in the prior year. This substantial drop indicates potential issues with product demand, market penetration, or competitive pressures.
• Shift to Net Loss and Reduced Profitability [high — financial]: The company reported a net loss of $4.760 million for the nine months ended September 30, 2025, a significant reversal from a net income of $0.276 million in the same period of 2024. Gross profit also fell 43.6% to $7.817 million, and operating income turned into an operating loss of $4.293 million.
• Facility Closure and Associated Costs [medium — operational]: Rockwell Medical closed its manufacturing facility in Greer, South Carolina, in Q3 2025, incurring $0.8 million in severance and closure-related costs. While intended to streamline operations, such closures can disrupt supply chains and impact production capacity in the short term.
• Decreasing Cash Position and Operating Cash Burn [high — financial]: Cash and cash equivalents decreased to $13.610 million as of September 30, 2025, from $15.662 million at December 31, 2024. The company also experienced net cash used in operating activities of $2.950 million for the nine months ended September 30, 2025, compared to cash provided by operations in the prior year.
• Reliance on ATM Facility for Liquidity [medium — financial]: While management believes it has sufficient funds for the next twelve months, a significant portion of its liquidity ($13.1 million) is available under an at-the-market (ATM) facility. This indicates a potential need for external financing if operational performance does not improve.
• Compliance with Healthcare Regulations [high — regulatory]: As a medical device company, Rockwell Medical is subject to stringent regulations from bodies like the FDA. Non-compliance or changes in regulatory requirements could lead to product recalls, fines, or market access restrictions, impacting sales and profitability.
• Competition in the Dialysis Market [medium — market]: The dialysis market is competitive, with established players and ongoing innovation. Failure to differentiate products or maintain a competitive pricing strategy could lead to market share erosion and impact revenue growth.
• Inventory Reduction and Working Capital Management [low — financial]: Inventory decreased from $5.778 million at December 31, 2024, to $3.964 million at September 30, 2025. While this can improve working capital, a significant drop might also signal reduced production or sales expectations.

Industry Context

Rockwell Medical operates in the highly regulated and competitive medical device sector, specifically focusing on products for the treatment of kidney disease. The industry is characterized by significant R&D investment, long product development cycles, and stringent regulatory hurdles from agencies like the FDA. Key trends include the increasing prevalence of chronic kidney disease globally and the development of innovative therapies and technologies to improve patient outcomes and reduce healthcare costs.

Regulatory Implications

As a medical device manufacturer, Rockwell Medical is subject to extensive regulatory oversight by the FDA and similar international bodies. Compliance with quality system regulations, pre-market approval processes, and post-market surveillance is critical. Any failure to comply, or changes in regulatory frameworks, could result in product recalls, manufacturing shutdowns, fines, and significant reputational damage, directly impacting financial performance and market access.

What Investors Should Do

1. Monitor revenue trends closely in the upcoming quarters.
2. Evaluate the company's cash burn rate and runway.
3. Assess the impact of the facility closure and operational streamlining.
4. Scrutinize the company's strategy for returning to profitability.

Key Dates

• 2025-09-30: End of Q3 2025 — Facility closure in Greer, SC occurred, incurring $0.8 million in costs. Financial results for the nine months ended this date show significant revenue decline and net loss.
• 2025-11-07: Shares of Common Stock Outstanding — Reported 39,405,302 shares outstanding, indicating potential dilution if ATM facility is utilized.

Glossary

At-the-Market (ATM) Facility

A type of equity offering where a company sells its shares directly into the open market over a period of time, typically through an underwriter. (Provides a source of potential additional capital for Rockwell Medical, but its utilization can dilute existing shareholders.)

Investments Available-for-Sale

Securities that are bought with the intention of selling them in the near term, but not for trading purposes. They are reported at fair value on the balance sheet. (Represents a portion of Rockwell Medical's liquid assets, which increased from $5.940 million to $10.097 million.)

Right of Use Assets - Operating

Represents the value of a company's right to use an asset (like a building or equipment) over the lease term, recognized under ASC 842 lease accounting standards. (Reflects obligations related to operating leases, which have decreased from $3.215 million to $2.991 million.)

Deferred Consideration

Payments that are owed to a seller in a business acquisition that are to be paid at a future date, contingent on certain performance milestones or time. (Represents future payment obligations, which have decreased from $3.371 million to $1.750 million in current liabilities and from $1.000 million to zero in long-term liabilities.)

Accumulated Deficit

The cumulative net losses of a company since its inception, less any net income. It represents a negative retained earnings balance. (Rockwell Medical has a significant accumulated deficit of $(402.438) million as of September 30, 2025, reflecting its history of losses.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Rockwell Medical has experienced a severe downturn in financial performance. Net sales have plummeted by 33.7% from $76.824 million to $50.912 million, directly contributing to a swing from net income of $0.276 million to a net loss of $4.760 million. Gross profit margins have compressed significantly, and operating income has reversed into a substantial operating loss. Cash reserves have also decreased, and the company has shifted from generating operating cash flow to consuming it, highlighting a deteriorating financial condition.

Key Financial Figures

• $0.0001 — ch registered: Common Stock, par value $0.0001 RMTI Nasdaq Capital Market The number

Filing Documents

• rmti-20250930.htm (10-Q) — 1150KB
• rmti-20250930x10qex311.htm (EX-31.1) — 9KB
• rmti-20250930x10qex312.htm (EX-31.2) — 9KB
• rmti-20250930x10qex321.htm (EX-32.1) — 4KB
• rmti-20250930x10qex322.htm (EX-32.2) — 4KB
• 0001628280-25-051290.txt ( ) — 7866KB
• rmti-20250930.xsd (EX-101.SCH) — 55KB
• rmti-20250930_cal.xml (EX-101.CAL) — 89KB
• rmti-20250930_def.xml (EX-101.DEF) — 298KB
• rmti-20250930_lab.xml (EX-101.LAB) — 726KB
• rmti-20250930_pre.xml (EX-101.PRE) — 536KB
• rmti-20250930_htm.xml (XML) — 1146KB

— Financial Information (unaudited)

Part I — Financial Information (unaudited)

- Unaudited Financial Statements

Item 1 - Unaudited Financial Statements Condensed Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Comprehensive ( Loss ) Income for the Three and Nine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 7 Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements 9

- Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations 16

- Quantitative and Qualitative Disclosures about Market Risk

Item 3 - Quantitative and Qualitative Disclosures about Market Risk 18

- Controls and Procedures

Item 4 - Controls and Procedures 19

— Other Information

Part II — Other Information

- Legal Proceedings

Item 1 - Legal Proceedings 19

- Risk Factors

Item 1A - Risk Factors 19

- Unregistered Sales of Equity Securities and Use of Proceeds

Item 2 - Unregistered Sales of Equity Securities and Use of Proceeds 19

- Defaults Upon Senior Securities

Item 3 - Defaults Upon Senior Securities 19

- Mine Safety Disclosures

Item 4 - Mine Safety Disclosures 19

- Other Information

Item 5 - Other Information 20

- Exhibits

Item 6 - Exhibits 20

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements ROCKWELL MEDICAL, INC. AND SUBSIDIARIES UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share and par value amounts) September 30, 2025 December 31, 2024 ASSETS Cash and Cash Equivalents $ 13,610 $ 15,662 Investments Available-for-Sale 10,097 5,940 Accounts Receivable, net 8,328 8,291 Inventory, net 3,964 5,778 Prepaid and Other Current Assets 1,515 1,359 Total Current Assets 37,514 37,030 Property and Equipment, net 4,952 5,785 Inventory, Non-Current — 178 Right of Use Assets - Operating, net 2,991 3,215 Right of Use Assets - Finance, net 753 1,344 Intangible Assets, net 9,794 10,207 Goodwill 921 921 Other Non-Current Assets 561 528 Total Assets $ 57,486 $ 59,208 LIABILITIES AND STOCKHOLDERS' EQUITY Accounts Payable $ 1,523 $ 2,869 Accrued Liabilities 3,865 6,275 Deferred Consideration - Current 1,750 2,371 Lease Liabilities - Operating - Current 1,318 1,566 Lease Liabilities - Finance - Current 461 599 Deferred License Revenue - Current — 46 Insurance Financing Note Payable 462 268 Customer Deposits 203 97 Total Current Liabilities 9,582 14,091 Lease Liabilities - Operating - Long-Term 1,724 1,699 Lease Liabilities - Financing - Long-Term 423 931 Term Loan - Long-Term, net of Issuance Costs 8,737 8,472 Deferred License Revenue - Long-Term — 429 Deferred Consideration - Long-Term — 1,000 Total Liabilities 20,466 26,622 Commitments and Contingencies (see Note 13) 3 September 30, 2025 December 31, 2024 Stockholders' Equity: Preferred Stock, $ 0.0001 par value, 2,000,000 shares authorized; 15,000 shares issued and outstanding at September 30, 2025 and December 31, 2024 — — Common Stock, $ 0.0001 par value; 170,000,000 shares authorized; 39,405,301 and 34,056,920 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 4 3 Additional Paid-in Capital 439,381 430,207 Accumulated Deficit ( 402,438 ) ( 397,678 ) Accumulated Other Compre

View Full Filing

View this 10-Q filing on SEC EDGAR